Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has provided an update.
An executive of ResMed Inc., officer Michael J. Rider, has filed a notice of proposed sale of company common stock under Rule 144, covering 50 shares to be sold on the NYSE through Fidelity Brokerage Services. The shares, valued at roughly $12,088 in aggregate, were acquired as restricted stock that vested in November 2023 as part of compensation, and follow a previous sale of 50 shares in December 2025, signaling a small, routine liquidity move rather than a material change in insider holdings or company operations.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. is a U.S.-based medical technology company focused on developing and manufacturing devices and software for the diagnosis, treatment and management of sleep-disordered breathing and respiratory conditions. Its primary products include continuous positive airway pressure (CPAP) machines, ventilators, and cloud-connected health solutions, serving patients, healthcare providers and sleep clinics globally, with a strong presence in the respiratory care and sleep apnea markets.
Average Trading Volume: 1,176,152
Technical Sentiment Signal: Buy
Current Market Cap: A$53.49B
For an in-depth examination of RMD stock, go to TipRanks’ Overview page.